Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because
Peanut allergy is the leading cause of food-related anaphylaxis, and accidental exposures are common. Oral immunotherapy (OIT) has been posited as a potential treatment.
Thirty percent of children with food allergy are allergic to more than one food. Previous studies on oral immunotherapy (OIT) for food allergy have focused on the administration of a single allergen at the time. This study aimed at evaluating the safety of a modified OIT protocol using multiple foods at one time.
Oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. We systematically reviewed the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo (no oral immunotherapy) for peanut allergy.
.
Despite progress in single food oral immunotherapy, there is little evidence concerning the safety and efficacy of treating individuals with multiple food (multifood) allergies. We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunotherapy benefited multifood allergic patients.
To report long-term follow-up data describing frequency and quantity of home dosing of food allergens following desensitization with multi-OIT protocols as part of two previously published phase 1 clinical trials.
“Peninsula Research Associates is conducting a clinical trial for oral immunotherapy.”
Palos Verdes Medical Group
550 Deep Valley Drive, Suite 319
Rolling Hills Estates, CA 90274
Copyright © 2023 – Palos Verdes Medical Group, Food Allergy Center. All Rights Reserved.
